[His1,Nle27] GHRF (1-32), amide, human
[His1,Nle27] GHRF (1-32), amide, human is a Growth hormone releasing hormone (GHRH) analog. [His1,Nle27] GHRF (1-32), amide, human has great receptor affinity for GHRHR.
For research use only. We do not sell to patients.
- CAS No.: 94034-78-3
- Formula: C159H265N51O46
- Molecular Weight:3627.12
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
![[His1,Nle27] GHRF (1-32), amide, human Chemical Structure](https://file.medchemexpress.com/product_pic/hy-p3594.gif "Click to View [His1,Nle27] GHRF (1-32), amide, human Chemical Structure")
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
In Vitro
[His1,Nle27] GHRF (1-32), amide, human (100 nM, 30 min) increases levels of c-fos and steel factor in Sertoli cell[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Sertoli cell
-
Concentration:100 nM
-
Incubation Time:30 min
-
Result:Increased c-fos mRNA expression by 20 min, and increased SCF transcript.
Chemical Information
-
CAS No. 94034-78-3
-
Molecular Weight 3627.12
-
Formula C159H265N51O46
-
Sequence Shortening
HADAIFTNSYRKVLGQLSARKLLQDI-{Nle}-SRQQG-NH2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
[His1,Nle27] GHRF (1-32), amide, human Related Classifications
HY-P3594 Related Classifications
Powered by Bioz